You can buy or sell BioTime and other stocks, options, ETFs, and crypto commission-free!
BioTime, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Read More Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
52 Week High
52 Week Low
Research And Development
Markets InsiderMar 18
BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 20th, 2019 at 2:45pm Eastern Time at the Westin New York Grand Central in the Track 2 Room in New York, NY. Interested parties can access a live audio webcast on the Events and Presentations section of BioTime’s website and an archived present...
Seeking AlphaMar 14
BioTime, Inc. (BTX) CEO Brian Culley on Q4 2018 Results - Earnings Call Transcript
BioTime, Inc. (NYSEMKT:BTX) Q4 2018 Results Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Ioana Hone - Investor Relations Brian Culley - Chief Executive Officer Brandi Robert - Chief Financial Officer Edward Wirth - CMO Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Naureen Quibria - Maxim Group Joseph Pantginis - H.C. Wainwright Reni Benjamin - Raymond James Keay Nakae - Chardan Operator Welcome to the BioTime, Inc. Fou...
Yahoo FinanceMar 14
BioTime: 4Q Earnings Snapshot
ALAMEDA, Calif. (AP) _ BioTime Inc. (BTX) on Thursday reported a loss of $45 million in its fourth quarter. The Alameda, California-based company said it had a loss of 35 cents per share. Losses, adjusted for non-recurring costs, came to 7 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was also for a loss of 7 cents per share. Scroll to continue with content Ad The biotechnology company posted revenue of $758,000 in ...
-$0.07 per share
-$0.36 per share